{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "N.D.",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "E",
            "alt": "K",
            "position": "46"
          },
          "Description in input context": "E46K"
        },
        {
          "HGVS": "N.D.",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "A",
            "alt": "P",
            "position": "30"
          },
          "Description in input context": "A30P"
        },
        {
          "HGVS": "N.D.",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T"
        },
        {
          "HGVS": "N.D.",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "A (at position 30) and A (at position 53)",
            "alt": "P (at position 30) and T (at position 53)",
            "position": "30 and 53"
          },
          "Description in input context": "A30P/A53T"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Lewy body diseases (LBD)",
    "MONDO": "N.D."
  },
  "Experiment Method": [
    {
      "Assay Method": "Thioflavin S (ThS) binding",
      "Material used": {
        "Material Source": "Recombinant Peptide Technologies",
        "Material Name": "Wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T)",
        "Description": "The αS solutions were prepared as described previously. Briefly, wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T) were purchased from Recombinant Peptide Technologies and were stored at - 80 °C. αS peptides were dissolved at a nominal concentration of 70 μM in 20 mM Tris buffer, pH 7.4."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D. (E46K)",
          "Conclusion": "Accelerated fαS formation compared to WT",
          "Molecular Effect": "Accelerated fαS formation, especially the elongation process",
          "Result Description": "E46K αS peptide accelerated fαS formation compared with the WT αS peptide. E46K, A53T and A30P/A53T αS peptides increased the growth rate meaning elongation phase compared with the WT αS peptide"
        },
        {
          "Variant": "N.D. (A30P)",
          "Conclusion": "Decelerated fαS formation compared to WT",
          "Molecular Effect": "Decelerated fαS formation, especially the elongation process",
          "Result Description": "A30P αS peptide decelerated fibril formation compared with WT αS peptide. The A30P peptide decreased the growth rate compared with the WT αS peptide"
        },
        {
          "Variant": "N.D. (A53T)",
          "Conclusion": "Accelerated fαS formation compared to WT",
          "Molecular Effect": "Accelerated fαS formation, especially the elongation process",
          "Result Description": "A53T αS peptide accelerated fαS formation compared with the WT αS peptide. E46K, A53T and A30P/A53T αS peptides increased the growth rate meaning elongation phase compared with the WT αS peptide"
        },
        {
          "Variant": "N.D. (A30P/A53T)",
          "Conclusion": "Accelerated fαS formation compared to WT",
          "Molecular Effect": "Accelerated fαS formation, especially the elongation process",
          "Result Description": "A30P/A53T αS peptide accelerated fαS formation compared with the WT αS peptide. E46K, A53T and A30P/A53T αS peptides increased the growth rate meaning elongation phase compared with the WT αS peptide"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Each figure comprises data obtained with 3 independent experiments."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Circular dichroism spectroscopy (CD)",
      "Material used": {
        "Material Source": "Recombinant Peptide Technologies",
        "Material Name": "Wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T)",
        "Description": "The αS solutions were prepared as described previously. Briefly, wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T) were purchased from Recombinant Peptide Technologies and were stored at - 80 °C. αS peptides were dissolved at a nominal concentration of 70 μM in 20 mM Tris buffer, pH 7.4."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D. (E46K)",
          "Conclusion": "Accelerated secondary structure change compared to WT",
          "Molecular Effect": "Accelerated SC → α/β → β secondary structure transitions",
          "Result Description": "E46K αS displayed substantially accelerated kinetic, with t1/2 ≈ 0.6 d. Conformational change in E46K αS was complete by day 2"
        },
        {
          "Variant": "N.D. (A30P)",
          "Conclusion": "Decelerated secondary structure change compared to WT",
          "Molecular Effect": "Decelerated SC → α/β → β secondary structure transitions",
          "Result Description": "A30P αS displayed substantial secondary structure changes during days 1 - 6, with t1/2 ≈ 1.6 d"
        },
        {
          "Variant": "N.D. (A53T)",
          "Conclusion": "Slightly accelerated secondary structure change compared to WT",
          "Molecular Effect": "Accelerated SC → α/β → β secondary structure transitions",
          "Result Description": "A53T αS peptides displayed slightly accelerated kinetics, with t1/2 ≈ 1.1 d. Conformational changes in the A53T αS peptides were complete by day 5"
        },
        {
          "Variant": "N.D. (A30P/A53T)",
          "Conclusion": "Slightly accelerated secondary structure change compared to WT",
          "Molecular Effect": "Accelerated SC → α/β → β secondary structure transitions",
          "Result Description": "A30P/A53T αS peptides displayed slightly accelerated kinetics, with t1/2 ≈ 1.1 d. Conformational changes in the A30P/A53T αS peptides were complete by day 5"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "The spectra presented at each time are representative of those obtained during each of 3 independent experiments."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Photo - induced cross - linking of unmodified proteins (PICUP) and sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS - PAGE)",
      "Material used": {
        "Material Source": "Recombinant Peptide Technologies",
        "Material Name": "Wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T)",
        "Description": "The αS solutions were prepared as described previously. Briefly, wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T) were purchased from Recombinant Peptide Technologies and were stored at - 80 °C. αS peptides were dissolved at a nominal concentration of 70 μM in 20 mM Tris buffer, pH 7.4."
      },
      "Readout type": "Qualitative (frequency distribution of monomers and oligomers)",
      "Readout description": [
        {
          "Variant": "N.D. (E46K)",
          "Conclusion": "Higher order oligomers compared to WT",
          "Molecular Effect": "Increased propensity to form relatively large oligomers",
          "Result Description": "When the oligomers were stabilized by cross - linking, E46K αS was composed of higher order species, including pentamers and hexamers. The oligomer/monomer ratio of E46K αS was 1.98 ± 0.07"
        },
        {
          "Variant": "N.D. (A30P)",
          "Conclusion": "Lower order oligomers compared to WT",
          "Molecular Effect": "Decreased propensity to form oligomers",
          "Result Description": "The oligomers of A30P αS were composed of monomers to trimers. The oligomer/monomer ratio of A30P αS was 0.73 ± 0.02"
        },
        {
          "Variant": "N.D. (A53T)",
          "Conclusion": "Similar oligomer distribution to WT",
          "Molecular Effect": "N.D.",
          "Result Description": "The oligomers of A53T αS showed a distribution similar to that of WT αS. The oligomer/monomer ratio of A53T αS was 1.63 ± 0.12"
        },
        {
          "Variant": "N.D. (A30P/A53T)",
          "Conclusion": "Similar oligomer distribution to WT",
          "Molecular Effect": "N.D.",
          "Result Description": "The oligomers of A30P/A53T αS peptides showed a distribution similar to that of WT αS. The oligomer/monomer ratio of A30P/A53T αS was 1.68 ± 0.12"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "The gel is representative of three independent experiments."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Non - cross - linked samples were used as controls in each experiment."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Densitometry was then performed using a luminescent image analyzer (LAS 4000 mini, Fujifilm, Tokyo) and image analysis software (Multi gauge version 3.2, Fujifilm)"
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Electron microscopy (EM)",
      "Material used": {
        "Material Source": "Recombinant Peptide Technologies",
        "Material Name": "Wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T)",
        "Description": "The αS solutions were prepared as described previously. Briefly, wild - type αS (WT), E46K mutant αS (E46K), A30P mutant αS (A30P), A53T mutant αS (A53T), and A30P/A53T mutant αS (A30P/A53T) were purchased from Recombinant Peptide Technologies and were stored at - 80 °C. αS peptides were dissolved at a nominal concentration of 70 μM in 20 mM Tris buffer, pH 7.4."
      }
    }
  ]
}